Other OTC - Delayed Quote USD

Aridis Pharmaceuticals, Inc. (ARDS)

0.0650 0.0000 (0.00%)
As of 12:35 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Eric J. Patzer Ph.D. Founder & Executive Chairman 240k -- 1949
Dr. Vu L. Truong Ph.D. Founder, CEO, Chief Scientific Officer & Director 631.65k -- 1964
Dr. Hasan Jafri M.D. Chief Medical Officer 559.36k -- 1967
Ms. Tamara S. Allen Vice President of Finance -- -- 1967
Mr. Jeffrey J. Fessler Esq., J.D. Acting General Counsel -- -- 1963

Aridis Pharmaceuticals, Inc.

983 University Avenue
Building B
Los Gatos, CA 95032
United States
408 385 1742 https://www.aridispharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
37

Description

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Corporate Governance

Aridis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 20, 2024 - May 24, 2024
Aridis Pharmaceuticals, Inc. Earnings Call

Related Tickers

PHRRF PharmaTher Holdings Ltd.
0.1675
-6.96%
 
RVPHW Reviva Pharmaceuticals Holdings, Inc.
0.5575
+18.62%
 
ACOGF Alpha Cognition Inc.
0.4928
-0.44%
 
OCUP Ocuphire Pharma, Inc.
1.5900
+3.58%
 
BCEL Atreca, Inc.
0.0864
+1.05%
 
EVAX Evaxion Biotech A/S
4.1500
+0.73%
 
CALC CalciMedica, Inc.
5.46
+0.00%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.9750
-0.17%
 
LPCN Lipocine Inc.
4.6400
+2.65%
 
NLSP NLS Pharmaceutics Ltd.
0.1355
+2.34%